AR079633A1 - Toxina clostridiana modificada de cadena unica, composicion farmaceutica que la comprende, molecula de polinucleotido que la codifica y metodo para producir dicha toxina - Google Patents

Toxina clostridiana modificada de cadena unica, composicion farmaceutica que la comprende, molecula de polinucleotido que la codifica y metodo para producir dicha toxina

Info

Publication number
AR079633A1
AR079633A1 ARP100104696A ARP100104696A AR079633A1 AR 079633 A1 AR079633 A1 AR 079633A1 AR P100104696 A ARP100104696 A AR P100104696A AR P100104696 A ARP100104696 A AR P100104696A AR 079633 A1 AR079633 A1 AR 079633A1
Authority
AR
Argentina
Prior art keywords
clostridian
toxin
binding domain
site
modified
Prior art date
Application number
ARP100104696A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR079633A1 publication Critical patent/AR079633A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/641—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22044—Nuclear-inclusion-a endopeptidase (3.4.22.44)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente memoria descriptiva describe también composiciones que comprenden un dominio de union al sitio de clivaje de proteasas integradas, moléculas de polinucleotidos que codifican dichas toxinas clostridianas y composiciones que comprenden formas de dicadena de esas toxinas clostridianas modificadas. Reivindicacion 1: Una toxina clostridiana modificada de cadena unica caracterizada porque comprende: a) un dominio enzimático de toxina clostridiana capaz de ejecutar un paso de modificacion de objetivo enzimático de un proceso de intoxicacion producido por la toxina clostridiana; b) un dominio de translocacion de la toxina clostridiana capaz de ejecutar un paso de translocacion de un proceso de intoxicacion de toxina clostridiana; y c) un dominio de union al sitio de clivaje de proteasas integradas que comprende una porcion P de un sitio de clivaje de proteasa que incluye el sitio P1 del enlace scissile y un dominio de union, donde el sitio P1 de la porcion P del sitio de clivaje de la proteasa linda con el extremo amino del dominio de union con lo cual se crea un sitio de clivaje de proteasa integrada; donde el clivaje del dominio de union al sitio de clivaje de proteasa integrada convierte la toxina clostridiana modificada de cadena unica en una forma de dicadena y produce un dominio de union con un terminal amino capaz de unirse a su receptor cognado.
ARP100104696A 2009-12-16 2010-12-16 Toxina clostridiana modificada de cadena unica, composicion farmaceutica que la comprende, molecula de polinucleotido que la codifica y metodo para producir dicha toxina AR079633A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28695409P 2009-12-16 2009-12-16

Publications (1)

Publication Number Publication Date
AR079633A1 true AR079633A1 (es) 2012-02-08

Family

ID=44341885

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104696A AR079633A1 (es) 2009-12-16 2010-12-16 Toxina clostridiana modificada de cadena unica, composicion farmaceutica que la comprende, molecula de polinucleotido que la codifica y metodo para producir dicha toxina

Country Status (14)

Country Link
US (2) US20110189162A1 (es)
EP (1) EP2512505A2 (es)
JP (1) JP2013514091A (es)
KR (1) KR20120107988A (es)
CN (1) CN102753681A (es)
AR (1) AR079633A1 (es)
AU (1) AU2010353292A1 (es)
CA (1) CA2784666A1 (es)
IL (1) IL220449A0 (es)
MX (1) MX2012006985A (es)
RU (1) RU2012129557A (es)
SG (1) SG181772A1 (es)
TW (1) TW201130974A (es)
WO (1) WO2011142783A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
WO2012051447A1 (en) 2010-10-14 2012-04-19 Allergan, Inc. Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders
US20120244188A1 (en) * 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251573A1 (en) * 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251575A1 (en) * 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
US20120251519A1 (en) * 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
WO2012135304A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Vagal nerve-based disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
US20130171122A1 (en) 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
EP4079316A1 (en) 2012-06-08 2022-10-26 Bioverativ Therapeutics Inc. Procoagulant compounds
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
BR112015003591B1 (pt) * 2012-11-21 2022-02-01 Ipsen Bioinnovation Limited Usos de lys-c e métodos para fabricação de um polipeptídeo proteoliticamente processado
EP2934571B1 (en) 2012-12-18 2018-05-30 Allergan, Inc. Prophylactic treatment of herpes recurrence
GB201312295D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Suppression of itch
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2015168471A1 (en) 2014-04-30 2015-11-05 Allergan, Inc. Formulations of biologics for intravesical instillation
EP3174523B1 (en) 2014-07-31 2020-07-01 Allergan, Inc. Formulations of biologics for intravesical instillation
EP3458472B1 (en) * 2016-05-16 2021-10-20 President and Fellows of Harvard College Method for purification and activation of botulinum neurotoxin
ES2939001T3 (es) * 2016-07-08 2023-04-18 Childrens Medical Center Una neurotoxina botulínica novedosa y sus derivados

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE220421T1 (de) 1990-02-26 2002-07-15 Univ Leland Stanford Junior Identifizierung und expression von insekten- steroidrezeptor-dns-sequenzen
CA2135644C (en) 1992-05-14 2009-01-27 Elisabetta Vegeto Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
WO2001014570A1 (en) 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
US20080032931A1 (en) 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20030219462A1 (en) 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7022329B2 (en) 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
DE602004009292T2 (de) * 2003-02-21 2009-03-19 Biotecnol S.A. Verwendung von caspasen zur herstellung von reifen rekombinanten fusionsproteinen
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
WO2006011966A1 (en) 2004-06-30 2006-02-02 Allergan, Inc. Optimizing expression of active botulinum toxin type e
CA2575994A1 (en) 2004-08-04 2006-02-16 Allergan, Inc. Optimizing expression of active botulinum toxin type a
EP1784420B1 (en) * 2004-09-01 2008-12-03 Allergan, Inc. Degradable clostridial toxins
CA2595115C (en) * 2004-12-01 2014-01-21 Health Protection Agency Fusion proteins for treating, preventing or ameliorating pain
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US20060155680A1 (en) * 2005-01-10 2006-07-13 Peng Wu Search file indicating languages associated with scenes
AU2006227816B2 (en) * 2005-03-15 2012-04-05 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
WO2008008803A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells

Also Published As

Publication number Publication date
EP2512505A2 (en) 2012-10-24
WO2011142783A2 (en) 2011-11-17
CA2784666A1 (en) 2011-11-17
JP2013514091A (ja) 2013-04-25
US20140127784A1 (en) 2014-05-08
AU2010353292A1 (en) 2012-07-12
MX2012006985A (es) 2012-09-12
RU2012129557A (ru) 2014-01-27
CN102753681A (zh) 2012-10-24
SG181772A1 (en) 2012-07-30
KR20120107988A (ko) 2012-10-04
US20110189162A1 (en) 2011-08-04
TW201130974A (en) 2011-09-16
IL220449A0 (en) 2012-08-30
WO2011142783A3 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
AR079633A1 (es) Toxina clostridiana modificada de cadena unica, composicion farmaceutica que la comprende, molecula de polinucleotido que la codifica y metodo para producir dicha toxina
PH12015500992A1 (en) Immuno-based retargeted endopeptidase activity assays
CL2011000672A1 (es) Anticuerpo que se une a il-17 humana; acido nucleico que lo codifica; vector de expresion; linea celular; metodo de produccion; composicion farmaceutica que lo comprende y su uso para tratar artritis reumatoidea entre otras enfermedades.
CL2009000284A1 (es) Antagonistas especificos de pro-proteina convertasa subtilisina-kexina tipo 9 humana (pcsk9), composicion farmaceutica que lo comprende; acidos nucleicos que lo codifican; vector, celula y proceso para producir dicho antagonista; util para mejorar un trastorno, afeccion o enfermedad inducida por pcsk9.
PE20140825A1 (es) Anticuerpos contra il-6 y sus usos
MA32712B1 (fr) Anticorps anti-vegf/anti-ang-2 bispecifique
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
MX2010010137A (es) Ensayos inmuno-basados de la actividad del serotipo a de la toxina botulinica.
EA201200091A1 (ru) Штаммы talaromyces и ферментные композиции
CO6440563A2 (es) Ensayos de actividad de endopeptidasa redirigida basados en inminoensayos
ATE371705T1 (de) Wässrige bitumenemulsion
PE20121516A1 (es) Antidotos de anticoagulantes
CR11461A (es) Formulacion de anticuerpo
CA2783820C (en) Protease variants
ATE498393T1 (de) Zusammensetzungen zur transportintensivierung durch die schleimhaut
EP3892709A3 (en) Variants and compositions comprising variants with high stability in presence of a chelating agent
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
MX2019013075A (es) Composiciones y metodos relacionados con una toxina mutante de clostridium difficile.
AR111673A1 (es) UNA PLANTA MODIFICADA POR INTRODUCCIÓN DE UNA MOLÉCULA DE ÁCIDO NUCLEICO QUE CODIFICA UNA m⁶ DESMETILASA Y EL MÉTODO PARA SU PRODUCCIÓN
BR112014001834A2 (pt) biocontrole de nematoides
AR066406A1 (es) Defensina de planta quimerica
BR112012015008B8 (pt) Processo para produção de um geopolímero
BR112017003483A2 (pt) composição de enzimas para solubilização de resíduos sólidos municipais, e, processo para solubilizar um resíduo sólido municipal, para produzir um produto de fermentação e para fermentar um resíduo sólido municipal
WO2010009879A3 (en) Methods for producing paricalcitol
CU23795A3 (es) Formulaciones líquidas de anticuerpo antirrábico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal